CoChat

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition

Open access
Srinivasan, Gayathri, Sidhu, Gurjit Singh, Williamson, Elizabeth A., Jaiswal, Aruna S., Najmunnisa, Nasreen, Wilcoxen, Keith, Jones, Dennie, George, Thomas J., Hromas, Robert · 2017 · Cancer Chemotherapy and Pharmacology
Cited by 60

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Malignant pleural mesotheliomas (MPM) are most often surgically unresectable, and they respond poorly to current chemotherapy and radiation therapy. Between 23 and 64% of malignant pleural mesothelioma have somatic inactivating mutations in the BAP1 gene. BAP1 is a homologous recombination (HR) DNA repair component found in the BRCA1/BARD1 complex. Similar to BRCA1/2 deficient cancers, mutation in the BAP1 gene leads to a deficient HR pathway and increases the reliance on other DNA repair pathways. We hypothesized that BAP1-mutant MPM would require PARP1 for survival, similar to the BRCA1/2 mutant breast and ovarian cancers. Therefore, we used the clinical PARP1 inhibitors niraparib and olaparib to assess whether they could induce synthetic lethality in MPM. Surprisingly, we found that all MPM cell lines examined, regardless of BAP1 status, were addicted to PARP1-mediated DNA repair for survival. We found that niraparib and olaparib exposure markedly decreased clonal survival in multiple MPM cell lines, with and without BAP1 mutations. This clonal cell death may be due to the extensive replication fork collapse and genomic instability that PARP1 inhibition induces in MPM cells. The requirement of MPM cells for PARP1 suggests that they may generally arise from defects in HR DNA repair. More importantly, these data demonstrate that the PARP1 inhibitors could be effective in the treatment of MPM, for which little effective therapy exists.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00280-017-3401-y

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 60

Metadata

Authors
Srinivasan, G., Sidhu, G. S., Williamson, E. A., Jaiswal, A. S., Najmunnisa, N., Wilcoxen, K., Jones, D., George, T. J., & Hromas, R.
Venue
Cancer Chemotherapy and Pharmacology
Published
2017-07-29
Volume
80
Issue
4
Pages
861-867
ISSN
  • 0344-5704 (ISSN-L)
  • 1432-0843
OpenAlex
W2741664311
Cited by
60
References
3
FWCI
2.48
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. https://app.cochat.ai/papers/10.1007/s00280-017-3401-y
The paper
Srinivasan, G., Sidhu, G. S., Williamson, E. A., Jaiswal, A. S., Najmunnisa, N., Wilcoxen, K., Jones, D., George, T. J., & Hromas, R. (2017). Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-017-3401-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.